Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury

Phase 2/3 Terminated 20 enrolled Pharmicell Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This phase II/III clinical trial is designed to evaluate the safety and efficacy of autologous Mesenchymal Stem Cells (MSC) transplanted directly into the injured spinal cord.

Timeline

Start: 2008-08
Primary completion: 2021-03-04
Completion: 2021-03-04

Publications

Background Park JH, Kim DY, Sung IY, Choi GH, Jeon MH, Kim KK, Jeon SR. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery. 2012 May;70(5):1238-47; discussion 1247. doi: 10.1227/NEU.0b013e31824387f9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mesenchymal stem cells	Cell therapy	1.6e+07 cells	Intrathecal
Subject	mesenchymal stem cells	Cell therapy	3.2e+07 cells	Intrathecal

Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury

Summary

Timeline

Publications

Drugs

Indications